Basic Information


GTO ID GTC0717
Trial ID ACTRN12622001514796
Disease Glioblastoma
Altered gene GD2
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment GD2 CAR-T cells
PhasePhase1
Recruitment statusRecruiting
TitleKARPOS - A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme
Year2022
CountryAustralia
Company sponsorRoyal Adelaide Hospital

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 1E7 cells/m^2, 3E7 cells/m^2, 1E8 cells/m^2
Donor type Autologous
Pts 18
Age Adult, Older_Adult
Lymph depletion Yes

Relationship Graph

Overview of Knowledge Graph